HUP0401009A2 - 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0401009A2 HUP0401009A2 HU0401009A HUP0401009A HUP0401009A2 HU P0401009 A2 HUP0401009 A2 HU P0401009A2 HU 0401009 A HU0401009 A HU 0401009A HU P0401009 A HUP0401009 A HU P0401009A HU P0401009 A2 HUP0401009 A2 HU P0401009A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- general formula
- atom
- alkyl
- aryl
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- -1 cycloheteroalkyl Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány az (I) általános képletű vegyületekre vonatkozik, aképletben W jelentése -SO2-, -C(O)-, -CONH-, -CSNH- vagy -CH2- képletűcsoport; X jelentése CR7 általános képletű csoport vagy nitrogénatom;Y jelentése CR8 általános képletű csoport vagy nitrogénatom, azzal amegkötéssel, hogy amikor X jelentése nitrogénatom, akkor Y jelentéseszükségképpen CR8 általános képletű csoport; Z jelentése oxigénatom, -SOP- vagy -N(R9)- általános képletű csoport; R1 és R2 jelentéseegymástól függetlenül hidrogénatom vagy alkilcsoport; n értéke 2, 3vagy 4; R3 és R4 jelentése egymástól függetlenül hidrogénatom, -CNR10NR11R12 általános képletű csoport vagy alkil-, alkenil-,alkinil-, cikloalkil-, cikloheteroalkil-, aril- vagy heteroaril-csoport, amelyek mindegyike adott esetben helyettesített, vagy R3 ésR4 a hozzájuk kapcsolódó atommal együtt adott esetben helyettesített3-6-tagú gyűrűt képezhet, amely adott esetben egy továbbiheteroatomot, mégpedig oxigén-, nitrogén- vagy kénatomot tartalmaz; R5jelentése hidrogén- vagy halogénatom, -OR13, -CO2R14, -CONR15R16 -CNR17NR18R19, -SO2NR20R21, -SOqR22 általános képletű csoport vagyciano-, alkil-, alkenil-, alkinil-, cikloalkil-, cikloheteroalkil-,fenil- vagy heteroarilcsoport, amelyek mindegyike adott esetbenhelyettesített; m értéke 1, 2 vagy 3. A találmány kiterjed a fentivegyületek előállítására és az ilyen vegyületeket tartalmazó, 5-HT6receptorral kapcsolatos vagy ezáltal befolyásolható központiidegrendszeri rendellenességek kezelésére alkalmasgyógyszerkészítményekre is. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26342501P | 2001-01-23 | 2001-01-23 | |
PCT/US2002/001950 WO2002059088A1 (en) | 2001-01-23 | 2002-01-18 | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0401009A2 true HUP0401009A2 (hu) | 2004-08-30 |
HUP0401009A3 HUP0401009A3 (en) | 2004-10-28 |
Family
ID=23001722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401009A HUP0401009A3 (en) | 2001-01-23 | 2002-01-18 | 1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them |
Country Status (23)
Country | Link |
---|---|
US (4) | US6509357B1 (hu) |
EP (1) | EP1353904B9 (hu) |
JP (1) | JP4208573B2 (hu) |
KR (1) | KR20030068591A (hu) |
CN (1) | CN1273450C (hu) |
AR (1) | AR034203A1 (hu) |
AT (1) | ATE312078T1 (hu) |
AU (1) | AU2002251811B2 (hu) |
BR (1) | BR0206633A (hu) |
CA (1) | CA2435566A1 (hu) |
DE (1) | DE60207815T2 (hu) |
DK (1) | DK1353904T3 (hu) |
EA (1) | EA006057B1 (hu) |
ES (1) | ES2250638T3 (hu) |
HU (1) | HUP0401009A3 (hu) |
IL (1) | IL157059A0 (hu) |
MX (1) | MXPA03006479A (hu) |
NO (1) | NO20033300L (hu) |
NZ (1) | NZ527051A (hu) |
PL (1) | PL364568A1 (hu) |
TW (1) | TW593278B (hu) |
WO (1) | WO2002059088A1 (hu) |
ZA (1) | ZA200306542B (hu) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1385842A1 (en) * | 2001-04-20 | 2004-02-04 | Wyeth | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
KR20030088507A (ko) * | 2001-04-20 | 2003-11-19 | 와이어쓰 | 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴알콕시-, -알킬티오- 및-알킬아미노벤즈아졸 유도체 |
DE60218037T2 (de) * | 2001-06-07 | 2007-08-23 | F. Hoffmann-La Roche Ag | Neue indolderivate mit affinität zum 5-ht6-rezeptor |
AU2003209114A1 (en) * | 2002-02-14 | 2003-09-04 | Wyeth | Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands |
KR100657056B1 (ko) | 2002-06-05 | 2006-12-13 | 에프. 호프만-라 로슈 아게 | 중추 신경계 장애의 치료를 위한 5-ht6-수용체조절제로서 1-설폰일-4-아미노알콕시 인돌 유도체 |
AU2003268117A1 (en) * | 2002-09-18 | 2004-04-08 | Eli Lilly And Company | Histamine h3 receptor antagonists, preparaton and therapeutic uses |
RU2350602C2 (ru) * | 2002-12-03 | 2009-03-27 | Ф.Хоффманн-Ля Рош Аг | Аминоалкоксииндолы, как лиганды рецептора 5-нт6, для лечения заболеваний цнс |
MXPA05008438A (es) * | 2003-02-14 | 2005-10-19 | Wyeth Corp | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6. |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
CA2557575A1 (en) | 2004-02-27 | 2005-09-15 | F. Hoffmann-La Roche Ag | Fused derivatives of pyrazole |
MXPA06009462A (es) | 2004-02-27 | 2007-03-15 | Hoffmann La Roche | Derivados pirazolo heteroaril fusionados. |
KR20060114022A (ko) | 2004-02-27 | 2006-11-03 | 에프. 호프만-라 로슈 아게 | 인다졸 유도체 및 그들을 함유하는 약학 조성물 |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
CA2815730C (en) * | 2004-10-08 | 2015-06-23 | I-Con Systems, Inc. | Diaphragm valve with electronic pressure detection |
MX2007005290A (es) | 2004-11-02 | 2007-07-09 | Pfizer | Derivados de sulfonilbencimidazol. |
BRPI0614343A2 (pt) * | 2005-08-15 | 2011-03-22 | Wyeth Corp | derivados de 3-sulfonilindazol substituìdo como ligantes de 5-hidroxitriptamina-6 |
BRPI0615442A2 (pt) | 2005-08-25 | 2011-05-17 | Hoffmann La Roche | inibidores de p38 map cinase e métodos para uso dos mesmos |
TW200804345A (en) * | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
DK1981851T3 (da) | 2006-01-31 | 2012-03-19 | Array Biopharma Inc | Kinaseinhibitorer og fremgangsmåder til anvendelse deraf |
CN101432274A (zh) * | 2006-04-05 | 2009-05-13 | 惠氏公司 | 作为5-羟色胺-6配体的磺酰基-3-杂环吲唑衍生物 |
WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
WO2007142905A2 (en) * | 2006-06-01 | 2007-12-13 | Wyeth | 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands |
US20090023925A1 (en) * | 2007-06-28 | 2009-01-22 | Wyeth | N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles |
NZ608069A (en) | 2010-10-06 | 2014-06-27 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
JP6454346B2 (ja) | 2013-12-20 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 芳香族複素環式化合物及び医薬におけるその応用 |
EP3166924B1 (en) | 2014-07-08 | 2019-02-20 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
CA3037587A1 (en) | 2016-09-30 | 2018-04-05 | Epizyme, Inc. | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors |
CN118021814A (zh) | 2017-04-21 | 2024-05-14 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
US11730736B2 (en) | 2017-11-06 | 2023-08-22 | Rapt Therapeutics, Inc. | Anticancer agents |
CN112847099A (zh) * | 2021-03-08 | 2021-05-28 | 王佳丽 | 一种有效调节进给量实现自动切割的砂轮切割机 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2905877A1 (de) * | 1979-02-16 | 1980-08-28 | Boehringer Mannheim Gmbh | Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
WO1995017398A1 (en) * | 1993-12-21 | 1995-06-29 | Smithkline Beecham Plc | Indole, indoline and quinoline derivatives with 5ht1d (anti-depressive) activity |
GB9416972D0 (en) | 1994-08-23 | 1994-10-12 | Smithkline Beecham Plc | Carbon side chain/indole/indolene |
EP0871442A1 (en) * | 1996-01-09 | 1998-10-21 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
GB9600344D0 (en) | 1996-01-09 | 1996-03-13 | Lilly Co Eli | Benzimidzolyl neuropeptide y receptor antagonists |
AU2139097A (en) * | 1996-03-01 | 1997-09-16 | Eli Lilly And Company | Methods of treating or preventing sleep apnea |
WO1998030548A1 (fr) | 1997-01-13 | 1998-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | AGONISTES DU RECEPTEUR 5-HT2c ET DERIVES D'AMINOALKYLINDAZOLE |
US6127380A (en) | 1997-02-18 | 2000-10-03 | American Home Products Corporation | 4-aminoalkoxy-1H-benzoimidazoles |
US5872144A (en) | 1997-02-18 | 1999-02-16 | American Home Products Corporation | 4-aminoethoxyindazole derivatives |
EA200001007A1 (ru) | 1998-03-31 | 2001-04-23 | Дюпон Фармасьютикалз Компани | Фармацевтические препараты для визуализации ангиогенных расстройств |
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
DK1140203T3 (da) * | 1998-12-18 | 2007-09-10 | Bristol Myers Squibb Pharma Co | Farmaceutiske præparater som vitronectinreceptorantagonist |
GB9902452D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB0019950D0 (en) * | 2000-08-12 | 2000-09-27 | Smithkline Beecham Plc | Compounds |
-
2001
- 2001-12-26 TW TW090132299A patent/TW593278B/zh not_active IP Right Cessation
-
2002
- 2002-01-18 EP EP02720837A patent/EP1353904B9/en not_active Expired - Lifetime
- 2002-01-18 JP JP2002559390A patent/JP4208573B2/ja not_active Expired - Fee Related
- 2002-01-18 MX MXPA03006479A patent/MXPA03006479A/es active IP Right Grant
- 2002-01-18 ES ES02720837T patent/ES2250638T3/es not_active Expired - Lifetime
- 2002-01-18 PL PL02364568A patent/PL364568A1/xx not_active Application Discontinuation
- 2002-01-18 WO PCT/US2002/001950 patent/WO2002059088A1/en active IP Right Grant
- 2002-01-18 DK DK02720837T patent/DK1353904T3/da active
- 2002-01-18 DE DE60207815T patent/DE60207815T2/de not_active Expired - Lifetime
- 2002-01-18 HU HU0401009A patent/HUP0401009A3/hu unknown
- 2002-01-18 KR KR10-2003-7009699A patent/KR20030068591A/ko not_active Application Discontinuation
- 2002-01-18 EA EA200300829A patent/EA006057B1/ru not_active IP Right Cessation
- 2002-01-18 AU AU2002251811A patent/AU2002251811B2/en not_active Ceased
- 2002-01-18 CA CA002435566A patent/CA2435566A1/en not_active Abandoned
- 2002-01-18 IL IL15705902A patent/IL157059A0/xx unknown
- 2002-01-18 CN CNB028067576A patent/CN1273450C/zh not_active Expired - Fee Related
- 2002-01-18 NZ NZ527051A patent/NZ527051A/en unknown
- 2002-01-18 BR BR0206633-5A patent/BR0206633A/pt not_active IP Right Cessation
- 2002-01-18 AT AT02720837T patent/ATE312078T1/de not_active IP Right Cessation
- 2002-01-22 US US10/055,365 patent/US6509357B1/en not_active Expired - Fee Related
- 2002-01-22 AR ARP020100210A patent/AR034203A1/es not_active Application Discontinuation
- 2002-12-09 US US10/314,726 patent/US6710069B2/en not_active Expired - Fee Related
-
2003
- 2003-07-22 NO NO20033300A patent/NO20033300L/no not_active Application Discontinuation
- 2003-08-21 ZA ZA200306542A patent/ZA200306542B/xx unknown
- 2003-10-28 US US10/695,490 patent/US20040092564A1/en not_active Abandoned
- 2003-10-29 US US10/696,433 patent/US6919354B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401009A2 (hu) | 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
HUP0302167A2 (hu) | Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
HUP0401982A2 (hu) | Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
HUP0204083A2 (hu) | 2-Amino-nikotin-amid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és VEGF receptor tirozin kináz inhibitorként való alkalmazásuk | |
UA27238C2 (uk) | Індолінові похідні, а також їх фармацевтично прийнятні солі, що є антагоністами вазопресинових v1-рецепторів, спосіб їх одержання, проміжні продукти і фармацевтична композиція | |
ES2054825T3 (es) | Compuestos heterociclicos terapeuticos. | |
HUP0401339A2 (hu) | Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
MXPA05007496A (es) | Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes. | |
HUP0400682A2 (hu) | 5-Hidroxitriptamin-6-ligandumként használható heterociklilalkilindol- és -azaindol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0401083A2 (hu) | 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
HUP0301213A2 (hu) | Ciklin dependens kinázok amino-tiazol inhibitorai, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk | |
HUP0104188A2 (hu) | Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként | |
NO305209B1 (no) | N-alkyl-2-substituerte ATP-analoger, slike forbindelser til fremstilling av terapeutikum, farmas°ytisk preparat inneholdende slike forbindelser, og deres anvendelse | |
HUP0401241A2 (hu) | Új ciklohexil-szulfon-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0004024A2 (hu) | Azabenzimidazolvázas vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203895A2 (hu) | Szubsztituált azaindolok és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0203316A2 (hu) | Amino-triazolopiridin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0402317A2 (hu) | Szulfonamidszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0204245A2 (hu) | Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NO20050828L (no) | lndol-3-svovelderivater | |
HUP0402191A2 (hu) | Humán metabotrop glutamát receptor antagonista aktivitással rendelkező acetilénszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0202810A2 (hu) | Szubsztituált 2-tio-3.5-diciano-4-aril-6-aminopiridinek és eljárás az előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0402225A2 (hu) | Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |